Impact of edoxaban-related adverse events in patients with cancer experiencing venous thromboembolism during antineoplastic therapy: Results of the phase IV EDOI study (GOIRC-05-2018)
- PMID: 39970525
- DOI: 10.1016/j.ejca.2025.115296
Impact of edoxaban-related adverse events in patients with cancer experiencing venous thromboembolism during antineoplastic therapy: Results of the phase IV EDOI study (GOIRC-05-2018)
Abstract
Background: The oral factor Xa inhibitor, edoxaban, is effective and safe in cancer-associated Venous Thromboembolism (VTE) treatment. The EDOI study aims to evaluate compliance and quality of life (QoL) in patients with cancer-associated VTE treated with edoxaban during antineoplastic care.
Material and methods: The EDOI was a multicentre phase IV, single-arm study. Patients received edoxaban for at least 6 months. The primary objective was to evaluate the rate and 90 % Confidence Intervals of edoxaban-related adverse events (AEs) with impact on antineoplastic therapy in terms of delays, reduction, or interruption. Mixed models for repeated measure have been adopted to evaluate the secondary endpoint as the change of QoL scores from enrolment to 6 months.
Results: From July 2019 to March 2021, 147 patients were enrolled. Edoxaban-related AEs with impact on antineoplastic therapy were observed in 7 patients (4.76 %; 90 %CI 2.23 %-8.94 %). The cumulative incidence of AEs was 2.7 % at 1 month from enrolment. A statistically significant increase (p < 0.05) was observed for mean changes in PACT-Q2 Convenience (+5 points) and Satisfaction (at least +2.5), and reduction of ACTS Burden (at least +1.7) at 1 month. Overall QoL measured by FACT-G shows a mean increase in the first month (+1.3), while decreases in the subsequent 5 months (-2.5).
Conclusion: The results of the EDOI Study demonstrate that edoxaban was well tolerated in patients receiving cancer treatment, showing a low rate of AEs with an impact on antineoplastic therapy, mainly within the first 30 days of administration. Lastly, the edoxaban-related AEs did not result in a lower overall QoL.
Keywords: Adverse event; Cancer patients; Edoxaban; Phase IV; Quality of Life; VTE.
Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing interest CP: outside the submitted work personal fees for the advisory role, speaker engagements, and travel and accommodation expenses from Amgen, Astellas, AstraZeneca, Bayer, Bristol Meyer Squibb, Celgene, Daiichi Sankyo, , Eisai, Ipsen, Janssen, Incyte, Merck-Serono, Merck Sharp and Dohme, Novartis, Roche, Sandoz, Sanofi, and Servier. AD: outside the submitted work, has received personal fees for the advisory role, speaker engagements, and travel and accommodation expenses from Ipsen, Servier, BMS, Merck Serono, Amgen, and Daichii Sankyo. MT: received speakers’ and consultants’ fee from Astra-Zeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Takeda, Amgen, Merck, Sanofi, Janssen, Daiichi Sankyo. M.T. received institutional research grants from Astra-Zeneca, Boehringer Ingelheim and Roche. M.T. received travel support from Amgen and Takeda. FaG: honoraria for Advisory board/Speaker's bureau: Servier, Eli Lilly, Bristol-Myers Squibb, Iqvia, Merck Serono, Amgen, Pierre-Fabre. MM: reports honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Merck Serono, Merck Sharp & Dohme (MSD), Novartis, Roche, Takeda, Viatris, Ipsen for consultancy or participation to advisory boards; direct research funding from Tesaro/GlaxoSmithKline, institutional funding for work in clinical trials/contracted research from Beigene, Exelixis, MSD, Pfizer and Roche. Other authors have no COI..
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
